U-Neuron Biomedical

U-Neuron Biomedical Debt

The Debt of U-Neuron Biomedical (6973.TWO) as of Nov 22, 2026 is 4.90 M TWD. In the previous year, Debt was 9.66 M TWD — a change of -49.33% (lower).

Debt

4.90 MTWD

YoY

-49.33%

Last updated:

In 2024, U-Neuron Biomedical's total debt was 4.90 M TWD, a -49.33% change from the 9.66 M TWD total debt recorded in the previous year.

The U-Neuron Biomedical Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2021
0.00 TWD
Jan 1, 2022
4.40 M TWD
Jan 1, 2023
9.66 M TWD
Jan 1, 2024
4.90 M TWD
The U-Neuron Biomedical Debt history
YEARDebtYoY
4.90 MTWD-49.33%
9.66 MTWD+119.51%
4.40 MTWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Debt Details

Understanding U-Neuron Biomedical's Debt Structure

U-Neuron Biomedical's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing U-Neuron Biomedical's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to U-Neuron Biomedical’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in U-Neuron Biomedical’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about U-Neuron Biomedical stock

Debt of U-Neuron Biomedical is 4.90 M TWD in 2024.

Debt of U-Neuron Biomedical changed from 9.66 M TWD to 4.90 M TWD, representing a -49.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's U-Neuron Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — U-Neuron Biomedical

All Key Metrics — U-Neuron Biomedical